News|Articles|February 21, 2025

New Bat Coronavirus Has Capacity to Spread to Humans

Chinese researchers say this newly discovered virus can be transmitted to humans much the way COVID-19 did.

On nearly the 5 year anniversary when the US shutdown from the global COVID-19 pandemic, a report comes out of China that a bat coronavirus has the potential to be transmitted to humans.

The news comes from the lab of Shi Zhengli, PhD, the Chinese scientist infamous for research with bats and previous coronaviruses such as SARS-CoV-2. In a study published in Cell journal this week, Zhengli and her colleagues discovered HKU5-CoV lineage 2 (HKU5-CoV-2) virus in bats. This bat merbecovirus, HKU5-CoV-2, can use human ACE2 as a cell entry receptor to infect organisms.1-2

“This study reveals a distinct lineage of HKU5-CoVs in bats that efficiently use human ACE2 and underscores their potential zoonotic risk,” they wrote.2

What You Need to Know

Shi Zhengli's team identified a new bat merbecovirus, HKU5-CoV lineage 2 (HKU5-CoV-2), that can use the human ACE2 receptor to infect cells — the same entry point used by SARS-CoV-2. This raises concerns about its zoonotic potential and the risk of transmission to humans.

The study emphasizes the virus's efficient binding to human ACE2, suggesting a "high risk of spillover" either directly from bats or through an intermediate host. This virus shows a better adaptation to human ACE2 compared to its lineage 1 counterpart, increasing concerns about its potential to infect humans.

While the study underscores the zoonotic risk, researchers note that more investigation is needed to fully understand HKU5-CoV-2's spillover potential. The virus is related to MERS-CoV, known for severe respiratory illness, making continued surveillance and research critical to prevent future outbreaks.

“A high risk of spillover to humans, either through direct transmission or facilitated by intermediate hosts.”2

It is important to note, the investigators said the potential to have human spillover needed to be studied.

“Merbecoviruses comprise four viral species with remarkable genetic diversity: MERS-related coronavirus, Tylonycterisbat coronavirus HKU4, Pipistrellusbat coronavirus HKU5, and Hedgehog coronavirus 1. However, the potential human spillover risk of animal merbecoviruses remains to be investigated,” the authors wrote.

Essentially, HKU5-CoV-2 is related to the pathogen that causes Middle East respiratory syndrome (MERS).3

Still, the investigators showed concern over the potential of this virus to adapt compared to the first lineage of the virus.

“Structural and functional analyses indicate that HKU5-CoV-2 has a better adaptation to human ACE2 than lineage 1 HKU5-CoV. Authentic HKU5-CoV-2 infected human ACE2-expressing cell lines and human respiratory and enteric organoids. This study reveals a distinct lineage of HKU5-CoVs in bats that efficiently use human ACE2 and underscores their potential zoonotic risk,” noted the researchers.2

Zhengli is the director of the Center for Emerging Infectious Diseases at the Wuhan Institute of Virology (WIV).4 Shi Zhengli and colleagues found that bats are the natural reservoir of SARS-like coronaviruses, and she has been involved with COVID-19 research.4

References
1.FP News desk. Firstpost. February 21, 2025. Accessed February 21, 2025.
https://www.firstpost.com/world/chinese-bat-woman-finds-new-coronavirus-that-infects-humans-flags-high-spillover-risk-13865277.html
2. Chen J, Zhang W, Li Y, et al. Bat-infecting merbecovirus HKU5-CoV lineage 2 can use human ACE2 as a cell entry receptor. Cell. Published online February 12, 2025. doi:10.1016/j.cell.2025.01.042
3.Newfound bat virus that uses notorious receptor poses ‘spillover’ risk. Nature. February 19, 2025.Accessed February 21, 2025.
https://www.nature.com/articles/d41586-025-00503-7
4. Shi Zhengli.Wikipedia Accessed February 21, 2025
https://en.wikipedia.org/wiki/Shi_Zhengli


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.